Form 4: CorMedix CEO Joseph Todisco Exercises Stock Options, Acquires 59,170 Shares
SEC Form 4 Filing
CorMedix CEO Joseph Todisco exercised stock options to acquire 59,170 shares of common stock at $3.38 per share on April 1, 2025.
Summary
- On April 1, 2025, Joseph Todisco, CEO of CorMedix Inc., exercised stock options to acquire 59,170 shares of common stock.
- The exercise price was $3.38 per share.
- Following the transaction, Todisco directly owns 530,721 shares of CorMedix common stock.
- The options exercised were granted on May 10, 2022, and vest over four years in equal installments.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option exercise.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives.
Stakeholder Impact
- The transaction increases the CEO's stake in the company, potentially aligning his interests further with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/10/2022 | Date stock options were granted |
| 04/01/2025 | Date of transaction (exercise of stock options) |
| 04/02/2025 | Date of signature |
| 05/09/2032 | Expiration date of stock options |
Keywords
Form 4, insider trading, stock options, Joseph Todisco, CorMedix, CRMD, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.